CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← PRECISION BIOSCIENCES INC (DTIL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

PRECISION BIOSCIENCES INC (DTIL)

Biological Products, (No Diagnostic Substances) · market cap $185M · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Precision BioSciences (DTIL) is a Durham, NC-based clinical-stage gene editing company founded in 2006, built around its proprietary ARCUS genome editing platform. With a $226M market cap, ~$99.4M in cash, and a 25-month runway, the company operates a multi-asset pipeline spanning relapsed Non-Hodgkin's Lymphoma, Duchenne Muscular Dystrophy, metastatic pancreatic cancer, and NSCLC. The next near-term event is an earnings report on 2026-08-06, following a Phase 2 completion signal in June 2026.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
NPC-1C/NEO-102Phase 2Metastatic Pancreatic Cancer
NEO-201 in combination with pembrolizumabPhase 2Non Small Cell Lung Cancer
PBGENE-DMD (IV)Phase 2Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Price & technical context
3-month
-21.9%
6-month
-3.4%
12-month
+32.4%
52-wk range
$3.57–$10.60
vs 50-day MA
-1.3%
vs 200-day MA
+1.2%
Realized vol
72.6%
Max drawdown
-60.4%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for DTIL (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.